How to stay on top of new cancer research for someone you love

A cancer diagnosis hands a family a second, quieter job on top of the first one: keeping up. New clinical trials open every week. Studies publish. The FDA approves drugs and updates labels. Somewhere in that flow might be the thing that changes the conversation at your next appointment — and somewhere in it is a great deal of noise that will only exhaust you.

I learned this the hard way while researching options for my mom during her colorectal cancer. What follows isn't medical advice — I'm not a clinician, and neither is any tool. It's a system for staying informed and organized, so the people who are clinicians have something concrete to react to.

1. Get specific before you search

The single biggest mistake is searching for "cancer breakthroughs." Research is matched to detail, not to a diagnosis word. Before you read anything, write down — in one place — the things that actually narrow the field:

• The exact diagnosis. Not "lung cancer" but the histology and subtype (e.g., "non-small cell, adenocarcinoma").
• Stage and where it has spread. Trials and studies are often stage-specific.
• Biomarkers and mutations. KRAS, EGFR, HER2, MSI-high, PD-L1 status — these are frequently the entire basis a trial accepts or rejects someone.
• Treatments already tried. Many trials require you to have had (or not had) a prior therapy. "Treatment-naive" and "second-line" are different worlds.
• Practical limits. How far can you realistically travel? That alone filters most trial listings.

Keep that profile somewhere private and update it as things change. Every search you run later is only as good as this list.

2. Know the four sources worth watching

You don't need fifty bookmarks. Four public, authoritative sources cover the overwhelming majority of what matters, and each one links back to something you can verify:

• ClinicalTrials.gov — the U.S. registry of clinical trials. This is where you find what's recruiting, where, and the eligibility rules. (More on trials here.)
• PubMed — the index of peer-reviewed medical literature. New studies, results, and reviews land here.
• FDA drug updates — approvals, expanded indications, and safety/label changes for therapies.
• Preprints (e.g., Europe PMC) — early research before peer review. Useful as an early signal, but treat it as preliminary and unverified.

If a claim can't be traced to one of these (or a comparable registry/journal), be skeptical. The internet is full of confident summaries with no citation underneath.

3. Separate the signal from false hope

This is the emotional core of the whole exercise, so it deserves its own rule: a finding being real is not the same as it being relevant. A promising Phase I result in a different mutation, a trial three time zones away that isn't recruiting, a drug approved for a different stage — all real, none necessarily for your person.

For every interesting item, force yourself to answer three questions before you get attached to it:

1. Why might this fit? (the match)
2. Why might it not fit? (the disqualifiers — wrong subtype, wrong line of therapy, closed enrollment)
3. What do I still not know? (the gaps a clinician would need to fill in)

The goal is never to decide treatment. It's to walk into the appointment with a short list of specific, source-backed questions — not a folder of hope.

4. Make it a rhythm, not a marathon

Families burn out because they binge-research at 2 a.m. after a scary scan, then go dark for weeks. Research rewards the opposite: small, regular check-ins. Fifteen minutes on a set day each week beats a frantic six-hour session once a month. Set a recurring time, keep your running profile open, and only look for what's new since last time.

Capture anything worth raising in a single running document — date, source link, the three questions above. That document becomes the agenda for your next visit.

5. Bring it to the people who can act on it

Your oncology team is the filter that matters. Hand them something they can evaluate quickly: the specific trial number or study, why you flagged it, and the questions you have. A good clinician would rather spend two minutes on a citation than ten minutes untangling a vague "I read something online."

And when the answer is "that's not right for us, and here's why" — that's a win too. Ruling things out with a reason is exactly what this system is for.

← Back to the blog  ·  Next: questions to ask about clinical trials →